Bone Biologics (BBLG) Cash from Operations (2013 - 2025)
Bone Biologics (BBLG) posted quarterly Cash from Operations of 723612.0 for Q4 2025, up 46.54% year-over-year from 493806.37 in Q4 2024, and down 22.36% quarter-over-quarter from 591384.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Cash from Operations (2013 - 2025) Analysis & Trends
Bone Biologics (BBLG) has reported Cash from Operations for 14 consecutive years, with 723612.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Cash from Operations rose 46.54% year-over-year to 723612.0; the TTM figure through Dec 2025 stood at 2700000.0 (up 34.54% YoY), while the FY2025 annual figure was 2700000.0, up 34.54% from the prior year.
- Cash from Operations eased to 723612.0 in Q4 2025 per BBLG's latest filing, from 591384.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 127983.0 in Q1 2021 and bottomed at 3632673.0 in Q2 2023.
- Historically, Cash from Operations has averaged 1058816.9 across 5 years, with a median of 792195.5 in 2022.
- Annual changes were most pronounced in 2022 — Cash from Operations sank 944.03% — and 2024, when it surged 77.61%.
- Bone Biologics' Cash from Operations stood at 186852.0 in 2021, then tumbled by 944.03% to 1950791.0 in 2022, then decreased by 3.45% to 2018015.0 in 2023, then soared by 32.93% to 1353497.0 in 2024, then soared by 46.54% to 723612.0 in 2025.
- Business Quant data shows BBLG's Cash from Operations at 723612.0 in Q4 2025, 591384.0 in Q3 2025, and 458879.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -700,000.00 |
| Sep 30, 2025 | -614,996.00 |
| Jun 30, 2025 | -458,879.00 |
| Mar 31, 2025 | -926,125.00 |
| Dec 31, 2024 | -1.35 Mn |
| Sep 30, 2024 | -572,162.00 |
| Jun 30, 2024 | -895,865.00 |
| Mar 31, 2024 | -1.30 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -2.56 Mn |
| Jun 30, 2023 | -3.63 Mn |
| Mar 31, 2023 | -1.35 Mn |
| Dec 31, 2022 | -1.95 Mn |
| Sep 30, 2022 | -395,279.00 |
| Jun 30, 2022 | -360,064.00 |
| Mar 31, 2022 | -860,779.00 |
| Dec 31, 2021 | -186,852.00 |
| Sep 30, 2021 | -277,770.00 |
| Jun 30, 2021 | -635,981.00 |
| Mar 31, 2021 | -127,983.00 |